RxDoctor Payments Data

Rajesh Thiraviam Pillai, MD

Family Medicine · Phoenix, AZNPI 1700801602

Payments from drug & device makers

$2,806in general payments, 2019–2025

Across 118 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$411
  • Amgen$362
  • Abbott$304
  • Boston Scientific$230
  • Abiomed$177
  • GSK$168
  • plus $1K from 26 others
$19,768in research payments, 2019–2025

Across 1 payment — averaging $19,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • HRA Pharma$20K

What the payments were for

  • Food & beverage$2,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,806 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$71,684
Medicare patients
71
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate40$56,877
JardianceEmpagliflozin30$30,992
OzempicSemaglutide23$24,086
EliquisApixaban12$7,096
Epinephrine11$2,646
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,151
Atorvastatin Calcium217$1,637
Metoprolol Succinate105$1,238
Gabapentin61$1,022
Omeprazole68$942
Fluticasone Propionate59$915
Albuterol Sulfate HfaAlbuterol Sulfate42$895
Lisinopril132$799
Levothyroxine Sodium102$749
Losartan Potassium99$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$124$56,87740 claims
Boehringer IngelheimJardiance$411$30,99230 claims
Novo NordiskOzempic$92$24,08623 claims
PfizerEliquis$112$7,09612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →